Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Evelio Garcia

Internal Medicine Hayti, SD Medical Doctor

NPI 1669436200 CMS profile 120349

102 Main Ave, Hayti, SD 57241

Open in the dashboard

General payments

$2,313

122 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Evelio Garcia of Hayti, SD is reported in the CMS Open Payments database as having received $2,313 across 122 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $93 2
2022 General $14 1
2021 General $790 45
2020 General $514 28
2019 General $902 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Evelio Garcia
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Evelio Garcia were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Evelio Garcia Internal Medicine median Middle half National median
2019 $902 $159 $48–$570 $163
2020 $514 $119 $33–$402 $114
2021 $790 $135 $37–$521 $132
2022 $14 $141 $42–$496 $149
2023 $93 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Abbott Laboratories $1,163 39 payments
  2. Janssen Pharmaceuticals, Inc $385 28 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $143 18 payments
  4. Cardiovascular Systems Inc. $138 8 payments
  5. Amgen Inc. $112 5 payments
  6. Sanofi-Aventis U.S. LLC $81 5 payments
  7. E.R. Squibb & Sons, L.L.C. $80 5 payments
  8. Novartis Pharmaceuticals Corporation $59 4 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $45 3 payments
  10. AstraZeneca Pharmaceuticals LP $34 2 payments
  11. Other $72 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,313 122 payments
Products named General payments · program years 2019–2023
  1. Assurity Pacemaker Cardiac Arrhythmias and Heart Failure $461 12 payments
  2. XARELTO $385 28 payments
  3. LifeVest $143 18 payments
  4. Quadra Assura CRT Defibrillator $134 4 payments
  5. Quartet CRT Lead $112 5 payments
  6. Repatha $112 5 payments
  7. Assurity Pacemaker Cardiac Rhythm Management $105 5 payments
  8. PRALUENT $81 5 payments
  9. ELIQUIS $80 5 payments
  10. Corlanor $75 3 payments
  11. Other $713 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

127

Median for Cardiology: 2,533

Drug cost

$24,396

Median for Cardiology: $485,213

Branded share of claims

47.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 25 $15,913
Entresto Sacubitril/Valsartan Brand 12 $7,427
Metoprolol Succinate Generic 26 $471
Amiodarone Hcl Generic 19 $378
Carvedilol Generic 22 $80
Clopidogrel Clopidogrel Bisulfate Brand 11 $79
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 12 $49

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$13,371

Medicare's payments for the services billed

Medicare patients

102

Average age 77

Services billed

205

46 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 52%
Atrial fibrillation 44%
Arthritis 40%
Diabetes 33%
Heart failure 30%
Chronic kidney disease 25%
Depression 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

122 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record